Sam Brusco, Associate Editor09.14.22
Conformis has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Actera hip system.
Actera adds a tri-taper femoral stem design to the company’s hip portfolio. Its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier femur access, less injury to muscles, and fewer potential nerve interactions.
“We’re excited to expand Conformis’ hip portfolio with the addition of Actera, to satisfy the rise in surgeon demand for tri-taper stems,” Mark Augusti, CEO and president of Conformis told the press. “Surgeons have demonstrated a significant and growing preference for anterior total hip arthroplasty (THA) surgeries in recent years, and the innovative tri-taper stem is designed for easier placement. Peer-reviewed studies provide an increasing body of evidence that a tri-taper stem supports improved proximal load transfer and lower likelihood of implant loosening.”
Conformis will initiate limited release of Actera in select U.S. markets, which is expected to commence in the coming months. The complete THA system and supporting software aims to offer more personalized alternatives to cementless hip stems on market, while leveraging the company’s advanced surgical planning and surgery in a box delivery model.
“The Actera hip, with its tri-tapered stem, is the natural evolution of the Conformis personalized portfolio,” said Dr. Robert T. Trousdale, M.D., a Board-certified orthopedic surgeon at the Mayo Clinic in Rochester, Minn. “It is well-suited to whichever surgical approach is chosen by the surgeon.”
Actera adds a tri-taper femoral stem design to the company’s hip portfolio. Its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier femur access, less injury to muscles, and fewer potential nerve interactions.
“We’re excited to expand Conformis’ hip portfolio with the addition of Actera, to satisfy the rise in surgeon demand for tri-taper stems,” Mark Augusti, CEO and president of Conformis told the press. “Surgeons have demonstrated a significant and growing preference for anterior total hip arthroplasty (THA) surgeries in recent years, and the innovative tri-taper stem is designed for easier placement. Peer-reviewed studies provide an increasing body of evidence that a tri-taper stem supports improved proximal load transfer and lower likelihood of implant loosening.”
Conformis will initiate limited release of Actera in select U.S. markets, which is expected to commence in the coming months. The complete THA system and supporting software aims to offer more personalized alternatives to cementless hip stems on market, while leveraging the company’s advanced surgical planning and surgery in a box delivery model.
“The Actera hip, with its tri-tapered stem, is the natural evolution of the Conformis personalized portfolio,” said Dr. Robert T. Trousdale, M.D., a Board-certified orthopedic surgeon at the Mayo Clinic in Rochester, Minn. “It is well-suited to whichever surgical approach is chosen by the surgeon.”